TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. GLOBAL CANCER SUPPORTIVE CARE MARKET, BY TYPE
6.1. Overview
6.2. ESA (Erythropoiesis-Stimulating Agents)
6.3. G-CSFs (Granulocyte Colony-Stimulating Factors)
6.4. Antiemetics
6.5. Bisphosphonates
6.6. Opioids
6.7. NSAIDs (Non-Steroidal Auto Inflammatory Drugs)
6.8. Others
7. GLOBAL CANCER SUPPORTIVE CARE MARKET, BY APPLICATION
7.1. Overview
7.2. Breast Cancer
7.3. Lung Cancer
7.4. Colorectal Cancer
7.5. Prostate Cancer
7.6. Liver Cancer
7.7. Stomach Cancer
7.8. Others
8. GLOBAL CANCER SUPPORTIVE CARE MARKET, BY END-USE
8.1. Overview
8.2. Hospital Pharmacies
8.3. Drug Stores and Retail Pharmacies
8.4. Online Providers
9. GLOBAL CANCER SUPPORTIVE CARE MARKET, BY REGION
9.1. Overview
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. China
9.4.2. India
9.4.3. Japan
9.4.4. South Korea
9.4.5. Australia
9.4.6. Rest of Asia-Pacific
9.5. Rest of the World
9.5.1. Middle East
9.5.2. Africa
9.5.3. Latin America
10. COMPETITIVE LANDSCAPE
10.1. Overview
10.2. Competitive Analysis
10.3. Market Share Analysis
10.4. Major Growth Strategy in the Global Cancer Supportive Care Market,
10.5. Competitive Benchmarking
10.6. Leading Players in Terms of Number of Developments in the Global Cancer Supportive Care Market,
10.7. Key developments and Growth Strategies
10.7.1. New Type Launch/Application Deployment
10.7.2. Merger & Acquisitions
10.7.3. Joint Ventures
10.8. Major Players Financial Matrix
10.8.1. Sales & Operating Income, 2022
10.8.2. Major Players R&D Expenditure. 2022
11. COMPANY PROFILES
11.1. Amgen Inc.
11.1.1. Company Overview
11.1.2. Financial Overview
11.1.3. Product Offered
11.1.4. Key Developments
11.1.5. SWOT Analysis
11.1.6. Key Strategies
11.2. Baxter International Inc.
11.2.1. Company Overview
11.2.2. Financial Overview
11.2.3. Product Offered
11.2.4. Key Developments
11.2.5. SWOT Analysis
11.2.6. Key Strategies
11.3. F. Hoffmann-La Roche Ltd.
11.3.1. Company Overview
11.3.2. Financial Overview
11.3.3. Product Offered
11.3.4. Key Developments
11.3.5. SWOT Analysis
11.3.6. Key Strategies
11.4. GlaxoSmithKline Plc
11.4.1. Company Overview
11.4.2. Financial Overview
11.4.3. Product Offered
11.4.4. Key Developments
11.4.5. SWOT Analysis
11.4.6. Key Strategies
11.5. Helsinn Healthcare
11.5.1. Company Overview
11.5.2. Financial Overview
11.5.3. Product Offered
11.5.4. Key Developments
11.5.5. SWOT Analysis
11.5.6. Key Strategies
11.6. HERON THERAPEUTICS
11.6.1. Company Overview
11.6.2. Financial Overview
11.6.3. Product Offered
11.6.4. Key Developments
11.6.5. SWOT Analysis
11.6.6. Key Strategies
11.7. Johnson & Johnson
11.7.1. Company Overview
11.7.2. Financial Overview
11.7.3. Product Offered
11.7.4. Key Developments
11.7.5. SWOT Analysis
11.7.6. Key Strategies
11.8. Merck KGAA
11.8.1. Company Overview
11.8.2. Financial Overview
11.8.3. Product Offered
11.8.4. Key Developments
11.8.5. SWOT Analysis
11.8.6. Key Strategies
11.9. Novartis International AG
11.9.1. Company Overview
11.9.2. Financial Overview
11.9.3. Product Offered
11.9.4. Key Developments
11.9.5. SWOT Analysis
11.9.6. Key Strategies
11.10. Teva Pharmaceuticals
11.10.1. Company Overview
11.10.2. Financial Overview
11.10.3. Product Offered
11.10.4. Key Developments
11.10.5. SWOT Analysis
11.10.6. Key Strategies
12. APPENDIX
12.1. References
12.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL CANCER SUPPORTIVE CARE MARKET, SYNOPSIS, 2018-2032
TABLE 2 GLOBAL CANCER SUPPORTIVE CARE MARKET, ESTIMATES & FORECAST, 2018-2032 (USD BILLION)
TABLE 3 GLOBAL CANCER SUPPORTIVE CARE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 4 GLOBAL CANCER SUPPORTIVE CARE MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 5 GLOBAL CANCER SUPPORTIVE CARE MARKET, BY END-USE, 2018-2032 (USD BILLION)
TABLE 6 NORTH AMERICA CANCER SUPPORTIVE CARE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 7 NORTH AMERICA CANCER SUPPORTIVE CARE MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 8 NORTH AMERICA CANCER SUPPORTIVE CARE MARKET, BY END-USE, 2018-2032 (USD BILLION)
TABLE 9 NORTH AMERICA CANCER SUPPORTIVE CARE MARKET, BY COUNTRY, 2018-2032 (USD BILLION)
TABLE 10 U.S. CANCER SUPPORTIVE CARE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 11 U.S. CANCER SUPPORTIVE CARE MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 12 U.S. CANCER SUPPORTIVE CARE MARKET, BY END-USE, 2018-2032 (USD BILLION)
TABLE 13 CANADA CANCER SUPPORTIVE CARE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 14 CANADA CANCER SUPPORTIVE CARE MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 15 CANADA CANCER SUPPORTIVE CARE MARKET, BY END-USE, 2018-2032 (USD BILLION)
TABLE 16 EUROPE CANCER SUPPORTIVE CARE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 17 EUROPE CANCER SUPPORTIVE CARE MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 18 EUROPE CANCER SUPPORTIVE CARE MARKET, BY END-USE, 2018-2032 (USD BILLION)
TABLE 19 EUROPE CANCER SUPPORTIVE CARE MARKET, BY COUNTRY, 2018-2032 (USD BILLION)
TABLE 20 GERMANY CANCER SUPPORTIVE CARE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 21 GERMANY CANCER SUPPORTIVE CARE MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 22 GERMANY CANCER SUPPORTIVE CARE MARKET, BY END-USE, 2018-2032 (USD BILLION)
TABLE 23 FRANCE CANCER SUPPORTIVE CARE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 24 FRANCE CANCER SUPPORTIVE CARE MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 25 FRANCE CANCER SUPPORTIVE CARE MARKET, BY END-USE, 2018-2032 (USD BILLION)
TABLE 26 ITALY CANCER SUPPORTIVE CARE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 27 ITALY CANCER SUPPORTIVE CARE MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 28 ITALY CANCER SUPPORTIVE CARE MARKET, BY END-USE, 2018-2032 (USD BILLION)
TABLE 29 SPAIN CANCER SUPPORTIVE CARE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 30 SPAIN CANCER SUPPORTIVE CARE MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 31 SPAIN CANCER SUPPORTIVE CARE MARKET, BY END-USE, 2018-2032 (USD BILLION)
TABLE 32 U.K CANCER SUPPORTIVE CARE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 33 U.K CANCER SUPPORTIVE CARE MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 34 U.K CANCER SUPPORTIVE CARE MARKET, BY END-USE, 2018-2032 (USD BILLION)
TABLE 35 REST OF EUROPE CANCER SUPPORTIVE CARE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 36 REST OF EUROPE CANCER SUPPORTIVE CARE MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 37 REST OF EUROPE CANCER SUPPORTIVE CARE MARKET, BY END-USE, 2018-2032 (USD BILLION)
TABLE 38 ASIA PACIFIC CANCER SUPPORTIVE CARE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 39 ASIA PACIFIC CANCER SUPPORTIVE CARE MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 40 ASIA PACIFIC CANCER SUPPORTIVE CARE MARKET, BY END-USE, 2018-2032 (USD BILLION)
TABLE 41 ASIA PACIFIC CANCER SUPPORTIVE CARE MARKET, BY COUNTRY, 2018-2032 (USD BILLION)
TABLE 42 JAPAN CANCER SUPPORTIVE CARE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 43 JAPAN CANCER SUPPORTIVE CARE MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 44 JAPAN CANCER SUPPORTIVE CARE MARKET, BY END-USE, 2018-2032 (USD BILLION)
TABLE 45 CHINA CANCER SUPPORTIVE CARE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 46 CHINA CANCER SUPPORTIVE CARE MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 47 CHINA CANCER SUPPORTIVE CARE MARKET, BY END-USE, 2018-2032 (USD BILLION)
TABLE 48 INDIA CANCER SUPPORTIVE CARE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 49 INDIA CANCER SUPPORTIVE CARE MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 50 INDIA CANCER SUPPORTIVE CARE MARKET, BY END-USE, 2018-2032 (USD BILLION)
TABLE 51 AUSTRALIA CANCER SUPPORTIVE CARE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 52 AUSTRALIA CANCER SUPPORTIVE CARE MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 53 AUSTRALIA CANCER SUPPORTIVE CARE MARKET, BY END-USE, 2018-2032 (USD BILLION)
TABLE 54 SOUTH KOREA CANCER SUPPORTIVE CARE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 55 SOUTH KOREA CANCER SUPPORTIVE CARE MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 56 SOUTH KOREA CANCER SUPPORTIVE CARE MARKET, BY END-USE, 2018-2032 (USD BILLION)
TABLE 57 REST OF ASIA-PACIFIC CANCER SUPPORTIVE CARE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 58 REST OF ASIA-PACIFIC CANCER SUPPORTIVE CARE MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 59 REST OF ASIA-PACIFIC CANCER SUPPORTIVE CARE MARKET, BY END-USE, 2018-2032 (USD BILLION)
TABLE 60 REST OF WORLD CANCER SUPPORTIVE CARE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 61 REST OF WORLD CANCER SUPPORTIVE CARE MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 62 REST OF WORLD CANCER SUPPORTIVE CARE MARKET, BY END-USE, 2018-2032 (USD BILLION)
TABLE 63 REST OF WORLD CANCER SUPPORTIVE CARE MARKET, BY COUNTRY, 2018-2032 (USD BILLION)
TABLE 64 MIDDLE EAST CANCER SUPPORTIVE CARE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 65 MIDDLE EAST CANCER SUPPORTIVE CARE MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 66 MIDDLE EAST CANCER SUPPORTIVE CARE MARKET, BY END-USE, 2018-2032 (USD BILLION)
TABLE 67 AFRICA CANCER SUPPORTIVE CARE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 68 AFRICA CANCER SUPPORTIVE CARE MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 69 AFRICA CANCER SUPPORTIVE CARE MARKET, BY END-USE, 2018-2032 (USD BILLION)
TABLE 70 LATIN AMERICA CANCER SUPPORTIVE CARE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 71 LATIN AMERICA CANCER SUPPORTIVE CARE MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 72 LATIN AMERICA CANCER SUPPORTIVE CARE MARKET, BY END-USE, 2018-2032 (USD BILLION) 
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL CANCER SUPPORTIVE CARE MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL CANCER SUPPORTIVE CARE MARKET
FIGURE 4 GLOBAL CANCER SUPPORTIVE CARE MARKET, SHARE (%), BY TYPE, 2022
FIGURE 5 GLOBAL CANCER SUPPORTIVE CARE MARKET, SHARE (%), BY APPLICATION, 2022
FIGURE 6 GLOBAL CANCER SUPPORTIVE CARE MARKET, SHARE (%), BY END-USE, 2022
FIGURE 7 GLOBAL CANCER SUPPORTIVE CARE MARKET, SHARE (%), BY REGION, 2022
FIGURE 8 NORTH AMERICA: CANCER SUPPORTIVE CARE MARKET, SHARE (%), BY REGION, 2022
FIGURE 9 EUROPE: CANCER SUPPORTIVE CARE MARKET, SHARE (%), BY REGION, 2022
FIGURE 10 ASIA-PACIFIC: CANCER SUPPORTIVE CARE MARKET, SHARE (%), BY REGION, 2022
FIGURE 11 REST OF THE WORLD: CANCER SUPPORTIVE CARE MARKET, SHARE (%), BY REGION, 2022
FIGURE 12 GLOBAL CANCER SUPPORTIVE CARE MARKET: COMPANY SHARE ANALYSIS, 2022 (%)
FIGURE 13 AMGEN INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 14 AMGEN INC.: SWOT ANALYSIS
FIGURE 15 BAXTER INTERNATIONAL INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 16 BAXTER INTERNATIONAL INC.: SWOT ANALYSIS
FIGURE 17 F. HOFFMANN-LA ROCHE LTD.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 18 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS
FIGURE 19 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 20 GLAXOSMITHKLINE PLC: SWOT ANALYSIS
FIGURE 21 HELSINN HEALTHCARE.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 22 HELSINN HEALTHCARE.: SWOT ANALYSIS
FIGURE 23 HERON THERAPEUTICS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 24 HERON THERAPEUTICS: SWOT ANALYSIS
FIGURE 25 JOHNSON & JOHNSON: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 26 JOHNSON & JOHNSON: SWOT ANALYSIS
FIGURE 27 MERCK KGAA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 28 MERCK KGAA: SWOT ANALYSIS
FIGURE 29 NOVARTIS INTERNATIONAL AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 30 NOVARTIS INTERNATIONAL AG: SWOT ANALYSIS
FIGURE 31 TEVA PHARMACEUTICALS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 32 TEVA PHARMACEUTICALS: SWOT ANALYSIS
